ABTABT: Abbott Plans Nutrition Spin-Off
Abbott (ABT) will separate its global nutrition unit into a standalone company. Key segment figures, risks and investor context as of 2026-10-21.
ABBOTT LABORATORIES
ABTAbbott (ABT) to Acquire Exact Sciences — $20B Notes, Cash
Abbott (ABT) announces intent to acquire Exact Sciences on 2026-03-09, funded by $20B notes and cash. Analysis of funding, business segments, and risks.
ABBOTT LABORATORIES
ABTAbbott (ABT) to Acquire Exact Sciences
Abbott (ABT) announces intent to acquire Exact Sciences, funded with $20B notes and cash. Analysis of financing, segment implications, governance and risks (2026-03-09).
ABBOTT LABORATORIES
ABTAbbott Issues $20B Senior Notes to Fund Exact Sciences
Abbott (ABT) raises $20B through senior notes to finance its acquisition of Exact Sciences. Details, context, and investor implications as of 2026-03-09.
ABBOTT LABORATORIES
ABTABT: Abbott Labs Board Reduced to 12 (2026)
Abbott Laboratories (ABT) trims its board from 13 to 12 members, effective 2026. Key governance context and what investors should watch next.
ABBOTT LABORATORIES
ABTAbbott (ABT) Adds Nita Ahuja to Board
Abbott Laboratories (ABT) appointed Nita Ahuja to its board, increasing the board to 13 members. Governance and investor implications for Abbott's strategic priorities.
ABBOTT LABORATORIES
ABTABT: Abbott Labs Increases Board to 13, Revises Governance
Abbott Labs (ABT) expands its board to 13 and updates shareholder governance. Investor-focused summary with context from Q3 2025 results and key risks.
ABBOTT LABORATORIES
ABTAbbott Q3 & 9M 2025 Results — ABT Earnings
Abbott (ABT) posts double-digit EPS growth and higher sales in Q3 and nine months 2025; international revenue 61.2% of $32.9B nine-month sales.
ABBOTT LABORATORIES
ABTAbbott Gains Key Approvals for Heart Devices
Abbott (ABT) secures regulatory and guideline endorsements for cardiac devices, reinforcing its Medical Devices segment; revenue and risk analysis for investors.
ABBOTT LABORATORIES